Amicus Therapeutics, Inc. (NASDAQ:FOLD) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 33,645,830 shares, a decline of 4.4% from the July 14th total of 35,192,135 shares. Approximately 21.6% of the shares of the company are short sold. Based on an average daily trading volume, of 3,852,477 shares, the days-to-cover ratio is currently 8.7 days.

Amicus Therapeutics (NASDAQ:FOLD) opened at 12.05 on Friday. The stock has a 50 day moving average price of $12.20 and a 200 day moving average price of $8.49. The stock’s market capitalization is $1.98 billion. Amicus Therapeutics has a 12 month low of $4.41 and a 12 month high of $14.05.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.03. The business had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. During the same period last year, the firm earned ($0.40) earnings per share. On average, equities research analysts forecast that Amicus Therapeutics will post ($1.41) earnings per share for the current fiscal year.

In other Amicus Therapeutics news, insider Hung Do sold 29,914 shares of the business’s stock in a transaction on Friday, May 19th. The stock was sold at an average price of $8.00, for a total value of $239,312.00. Following the sale, the insider now directly owns 474,438 shares in the company, valued at $3,795,504. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Jay Barth sold 30,000 shares of the business’s stock in a transaction on Monday, June 19th. The shares were sold at an average price of $10.00, for a total value of $300,000.00. Following the completion of the sale, the insider now owns 64,184 shares in the company, valued at $641,840. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC acquired a new stake in Amicus Therapeutics during the second quarter worth approximately $282,000. FMR LLC boosted its stake in Amicus Therapeutics by 3.4% in the second quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock worth $215,876,000 after buying an additional 705,153 shares in the last quarter. Vanguard Group Inc. boosted its stake in Amicus Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock worth $91,821,000 after buying an additional 430,486 shares in the last quarter. Northern Trust Corp boosted its stake in Amicus Therapeutics by 3.1% in the second quarter. Northern Trust Corp now owns 1,738,010 shares of the biopharmaceutical company’s stock worth $17,502,000 after buying an additional 52,569 shares in the last quarter. Finally, Quantitative Investment Management LLC acquired a new stake in Amicus Therapeutics during the second quarter worth approximately $1,957,000.

Several equities analysts have recently weighed in on the company. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $15.00 price target (up from $13.00) on shares of Amicus Therapeutics in a research report on Wednesday. Chardan Capital lifted their price target on Amicus Therapeutics from $12.50 to $17.50 and gave the company a “buy” rating in a research report on Thursday. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. ValuEngine upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 9th. Finally, Cowen and Company reiterated a “buy” rating and issued a $16.00 price target (up from $10.00) on shares of Amicus Therapeutics in a research report on Tuesday, July 11th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Amicus Therapeutics has a consensus rating of “Buy” and an average target price of $14.58.

TRADEMARK VIOLATION WARNING: “Amicus Therapeutics, Inc. (FOLD) Short Interest Down 4.4% in July” was reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/amicus-therapeutics-inc-fold-short-interest-down-4-4-in-july/1476406.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.